Search

Your search keyword '"de Raaf, Pleun J"' showing total 13 results
Start Over Author "de Raaf, Pleun J"
13 results on '"de Raaf, Pleun J"'

1. Supplementary Table 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Author

de Graan, Anne-Joy M., primary, Elens, Laure, primary, Sprowl, Jason A., primary, Sparreboom, Alex, primary, Friberg, Lena E., primary, van der Holt, Bronno, primary, de Raaf, Pleun J., primary, de Bruijn, Peter, primary, Engels, Frederike K., primary, Eskens, Ferry A.L.M., primary, Wiemer, Erik A.C., primary, Verweij, Jaap, primary, Mathijssen, Ron H.J., primary, and van Schaik, Ron H.N., primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Author

de Graan, Anne-Joy M., primary, Elens, Laure, primary, Sprowl, Jason A., primary, Sparreboom, Alex, primary, Friberg, Lena E., primary, van der Holt, Bronno, primary, de Raaf, Pleun J., primary, de Bruijn, Peter, primary, Engels, Frederike K., primary, Eskens, Ferry A.L.M., primary, Wiemer, Erik A.C., primary, Verweij, Jaap, primary, Mathijssen, Ron H.J., primary, and van Schaik, Ron H.N., primary

Published
2023
Full Text
View/download PDF

7. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Author

de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A. L. M., Wiemer, Erik A. C., Verweij, Jaap, Mathijssen, Ron H. J., van Schaik, Ron H. N., de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A. L. M., Wiemer, Erik A. C., Verweij, Jaap, Mathijssen, Ron H. J., and van Schaik, Ron H. N.

Abstract

Purpose: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity. Experimental Design: In an exploratory cohort of patients (n = 261) treated with paclitaxel, neurotoxicity incidence, and severity, pharmacokinetic parameters and pharmacogenetic variants were determined. Paclitaxel plasma concentrations were measured by high-performance liquid chromatography or liquid chromatography/tandem mass spectrometry, and individual pharmacokinetic parameters were estimated from previously developed population pharmacokinetic models by nonlinear mixed effects modeling. Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C>T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239). Results: Exposure to paclitaxel ((log)AUC) was correlated with severity of neurotoxicity (P < 0.00001). Female CYP3A4*22 carriers were at increased risk of developing neurotoxicity (P = 0.043) in the exploratory cohort. CYP3A4*22 carrier status itself was not associated with pharmacokinetic parameters (CL, AUC, C-max, or T->0.05) of paclitaxel in males or females. Other genetic variants displayed no association with neurotoxicity. In the subsequent independent validation cohort, CYP3A4*22 carriers were at risk of developing grade 3 neurotoxicity (OR = 19.1; P = 0.001). Conclusions: Paclitaxel exposure showed a relationship with the severity of paclitaxel-induced neurotoxicity. In this study, female CYP3A4*22 carriers had increased risk of developing severe neurotoxicity during paclitaxel therapy. These observations may guide future individualization of paclitaxel treatment.

Published
2013
Full Text
View/download PDF

8. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

Author

UCL - SSS/LDRI - Louvain Drug Research Institute, de Graan, Anne-Joy M, Elens, Laure, Sprowl, Jason A, Sparreboom, Alex, Friberg, Lena E, van der Holt, Bronno, de Raaf, Pleun J, de Bruijn, Peter, Engels, Frederike K, Eskens, Ferry A L M, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N, UCL - SSS/LDRI - Louvain Drug Research Institute, de Graan, Anne-Joy M, Elens, Laure, Sprowl, Jason A, Sparreboom, Alex, Friberg, Lena E, van der Holt, Bronno, de Raaf, Pleun J, de Bruijn, Peter, Engels, Frederike K, Eskens, Ferry A L M, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, and van Schaik, Ron H N

Abstract

Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity.

Published
2013

10. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Author

de Graan, Anne-Joy M., primary, Elens, Laure, additional, Sprowl, Jason A., additional, Sparreboom, Alex, additional, Friberg, Lena E., additional, van der Holt, Bronno, additional, de Raaf, Pleun J., additional, de Bruijn, Peter, additional, Engels, Frederike K., additional, Eskens, Ferry A.L.M., additional, Wiemer, Erik A.C., additional, Verweij, Jaap, additional, Mathijssen, Ron H.J., additional, and van Schaik, Ron H.N., additional

Published
2013
Full Text
View/download PDF

13. Adherence to Analgesics in Oncology Outpatients: Focus on Taking Analgesics on Time.

Author

Oldenmenger WH, Sillevis Smitt PAE, de Raaf PJ, and van der Rijt CCD

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Pain etiology, Pain Management methods, Analgesics therapeutic use, Medication Adherence statistics & numerical data, Neoplasms complications, Outpatients statistics & numerical data, Pain drug therapy, Patient Education as Topic methods
Abstract

Background: Inadequate adherence to prescribed analgesics may be one of the reasons why patients with cancer experience unrelieved pain. Adherence is directly influenced by patients' barriers about pain management. Patient pain education programs (PEPs) have been developed to reduce patients' barriers and increase patients' adherence to their analgesics. The purpose of this article was to evaluate patients' adherence in patients receiving a pain consult and patient pain education in comparison with patients receiving standard pain treatment (standard care [SC]), to better explore the difficulties in medication adherence in cancer-related pain and the effects of PEP., Methods: In 54 adult outpatients with cancer-related pain, patients' adherence to the prescribed around-the-clock analgesics was measured with a Medication Event Monitoring System, in the following time intervals: weeks 1 and 2, weeks 3 and 4, and weeks 7 and 8 after randomization. Adherence was differentiated into taking adherence, taking the correct dose, and taking analgesics at the right time intervals., Results: Taking adherence increased in the intervention group compared to baseline (from 91% to 93%) and decreased in the SC group (from 85% to 78%; P < 0.05). At the end of the study, more patients in the intervention group took their analgesics at the right intervals (78%) than did patients in the SC group (64%, P < 0.05). During the study, patients were more adherent to opioids than to World Health Organization step 1 analgesics., Conclusion: The combined intervention can increase adherence. The true problem in pain management is that patients do not take their prescribed analgesics at the right time intervals. With the detailed adherence information from this study, it is possible to further tailor patient education to the individual patient., (© 2016 World Institute of Pain.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results